Drug intelligence / Profile preview

RAB-003

Development stage: Preclinical
Lead developer: Zhongshan Laibo Ruichen Biopharmaceutical
Modality: Peptides
Administration: Parenteral

Overview

RAB-003 is an early-stage peptide therapeutic under development by Zhongshan Laibo Ruichen Biopharmaceutical (Rabpharma) for the treatment of periodontitis. The drug was originally licensed from Regenerative Arthritis & Bone Medicine. It is part of Rabpharma's pipeline of innovative peptide-based therapeutics targeting bone and joint-related conditions. RAB-003 is currently in preclinical or early-stage development.

Beyond the preview

Go deeper on RAB-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAB-003.

Explore the full profile